A detailed history of Geode Capital Management, LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 3,240,379 shares of XERS stock, worth $9.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,240,379
Previous 3,045,364 6.4%
Holding current value
$9.33 Million
Previous $6.73 Million 8.32%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$1.7 - $2.45 $331,525 - $477,786
195,015 Added 6.4%
3,240,379 $7.29 Million
Q1 2024

May 13, 2024

BUY
$2.04 - $3.22 $312,705 - $493,584
153,287 Added 5.3%
3,045,364 $6.73 Million
Q4 2023

Feb 13, 2024

BUY
$1.47 - $2.36 $174,612 - $280,330
118,784 Added 4.28%
2,892,077 $6.8 Million
Q3 2023

Nov 13, 2023

BUY
$1.8 - $2.69 $164,678 - $246,102
91,488 Added 3.41%
2,773,293 $5.16 Million
Q2 2023

Aug 11, 2023

BUY
$1.82 - $2.98 $275,002 - $450,278
151,100 Added 5.97%
2,681,805 $7.03 Million
Q1 2023

May 15, 2023

BUY
$1.03 - $1.63 $100,933 - $159,730
97,994 Added 4.03%
2,530,705 $4.13 Million
Q4 2022

Feb 13, 2023

BUY
$1.14 - $1.65 $90,845 - $131,486
79,689 Added 3.39%
2,432,711 $3.24 Million
Q3 2022

Nov 14, 2022

BUY
$1.37 - $1.93 $245,871 - $346,373
179,468 Added 8.26%
2,353,022 $3.67 Million
Q2 2022

Aug 12, 2022

BUY
$1.48 - $2.64 $1.5 Million - $2.67 Million
1,011,664 Added 87.07%
2,173,554 $3.35 Million
Q1 2022

May 13, 2022

BUY
$2.0 - $2.87 $313,780 - $450,274
156,890 Added 15.61%
1,161,890 $2.97 Million
Q4 2021

Feb 11, 2022

BUY
$1.8 - $2.93 $541,494 - $881,431
300,830 Added 42.72%
1,005,000 $2.94 Million
Q3 2021

Nov 12, 2021

BUY
$2.2 - $4.25 $1.55 Million - $2.99 Million
704,170 New
704,170 $1.73 Million

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $392M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.